Yilmaz et al. prospectively evaluated decitabine and quizartinib (doublet) with or without venetoclax (triplet) in patients with newly diagnosed and R/R FLT3-ITDmut AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.